Debate contribution: Duchenne Muscular Dystrophy: Givinostat
Debate contribution by Mrs Linda Dillon on .
- MLA
- Mrs Linda Dillon
- Party at the time
- Sinn Féin
- Date
- 9 December 2024
- Type
- Debate contribution
- Business
- Oral Answers to Questions
- Heading
- Duchenne Muscular Dystrophy: Givinostat
- Assembly identifier
- Official Report component 4698536
Read the official Assembly record
Text
It was not my intention to get you, to be fair. If you can come back to us with an update, it will be appreciated. Givinostat has not yet been approved for licensing in the UK, but there is an early access programme, and access to it would be gratefully appreciated by the parents here. Children with DMD have an extremely life-limiting condition, which means that those children will not live to reach a very old age or, in many cases, even a young age. They really need access to whatever treatments are out there. If you could give us a written update, we would appreciate it. I think that the Chair of the Health Committee has written to you about the matter.
123 words. Text as published by the Northern Ireland Assembly.
Part of an exchange
This follow-up belongs to: Topical question AQT 856/22-27.
Assessment
Not analysed
This is the same MLA’s follow-up within the exchange on their own question. It is analysed together with that question and is not counted separately, so one question is never counted twice.
Disagree with this assessment?
Classifications can be challenged. A person reads every challenge, and any change is recorded publicly above with its reason.